ClinicalTrials.gg

Program

tolododekin alfa

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Skin Neoplasms, led by Ankyra Therapeutics.

Furthest: phase 1, since Nov 29, 20233 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ankyra Therapeutics32 open or runningphase 1since Nov 29, 2023Nov 29, 2023Apr 2027phase 1 · NCT06171750

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 29, 2023First study: phase 1 study in Skin NeoplasmsFirst studyNCT06171750 · 97 planned · United States, Canada
  2. Jun 11, 2025Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07027514 · 60 planned · United States
  3. Jul 28, 2025Phase 1 study in Cutaneous Squamous Cell Carcinoma (CSCC)NCT07100925

Ahead

  1. Apr 2027Primary completion: phase 1 study in Skin NeoplasmsNCT06171750
  2. Jun 30, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07027514

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07100925Cutaneous Squamous Cell Carcinoma (CSCC)1WithdrawnJun 20300
NCT07027514Carcinoma, Non-Small-Cell Lung · United States1RecruitingJun 30, 202760
NCT06171750Skin Neoplasms · United States, Canada1RecruitingApr 202797

How it is read

Names in the registry

  • “tolododekin alfa”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
tolododekin alfa (Ankyra Therapeutics): development program | ClinicalTrials.gg